The US FDA Approves BMS’ Opdivo + Yervoy as 1L Treatment for Hepatocellular Carcinoma (HCC)
Shots:
- The US FDA has approved Opdivo + Yervoy as 1L therapy to treat inoperable or advanced HCC adults
- Approval was based on P-III (CheckMate-9DW) trial assessing Opdivo (1mg/kg, Q3W) + Yervoy (3mg/kg, Q3W), followed by Opdivo alone (480mg, Q4W) vs lenvatinib/sorafenib in 668 pts with advanced HCC who had not received prior systemic therapy. In the comparator arm, 85% received lenvatinib, while 15% received sorafenib
- Study showed reduced death risk by 21% & improved OS of 38% vs 24% at 3yrs, with mOS of 23.7 vs 20.6mos. & ORR of 36.1% vs 13.2% (CR: 6.9% vs 1.8% & PR: 29.3% vs 11.4%); mDoR of 30.4 vs 12.9mos. & is not a powered endpoint
Ref: Businesswire | Image: BMS
Related News:- BMS Reports the US FDA’s Approval of Opdivo + Yervoy as a 1L Treatment of MSI-H/dMMR Metastatic Colorectal Cancer (mCRC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
